[53] exhibit the potential to downregulate the expression of phosphorylated vascular endothelial growth factor receptor 2 (VEGFR2) and CD31 in tumors, thereby demonstrating their ability to inhibit tumor angiogenesis. The gene discussed is KDR; the disease is neoplasm.